Spineguard (ALSGD) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Spineguard €0.01, price €0.09, upside -83.4%, quality 34 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Spineguard for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €0.0768 – €1.50 · the €0.0893 price screens above the €0.0148 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Spineguard in your weekly email
Every Wednesday you see whether Spineguard is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SpineGuard SA provides designs, develops, and markets medical devices for spine in France and internationally. The company offers PediGuard drilling instruments comprising straight, curved, cannulated, psifguard, and threaded PediGuard products; and DSG smart screw that allows for one step screw placement treatment.
Show more
SpineGuard SA provides designs, develops, and markets medical devices for spine in France and internationally. The company offers PediGuard drilling instruments comprising straight, curved, cannulated, psifguard, and threaded PediGuard products; and DSG smart screw that allows for one step screw placement treatment. It also provides DSG (Dynamic Surgical Guidance) Connect app that allows collection and visualization of the signal measured at the tip of DSG Connect devices during pedicle drilling, as well as DSG for orthopedic robots and dental implantology products. SpineGuard SA was incorporated in 2009 and is headquartered in Vincennes, France.
Stock analysis
Spineguard (ALSGD) currently trades at €0.0893, while our model-based Fair Value estimate is €0.0148, implying the stock looks roughly 503.5% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Spineguard reported revenue of €3.8M in FY2025 versus €4.4M in FY2021, a compound −3.9%/yr. Reported net income was −€2.1M in FY2025.
Key figures
Market cap €8.0M · P/S ratio 2.11 · EPS (TTM) €−0.0300 · Net margin −55.0% · Return on equity −44.1% · Return on assets (EBIT) −23.8% · Operating margin −56.0% · Revenue (TTM) €3.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −83%, ALSGD screens richer than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−19.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.0%
Start year 2020 (pandemic). Over 10 years: −4.9% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−37.8% (2020) → −44.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks
Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside−83% · Bottom 25%
Profitability
Return on assets−12% · Bottom 25%
Net margin (TTM)−55% · Bottom 25%
Operating margin (TTM)−56% · Bottom 25%
Growth and dividend
Revenue growth−26% · Bottom 25%
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B1.66× · Pricier than median
P/S (TTM)2.41× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 11
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 8
HEALTH (low debt)93· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Spineguard Fair Value". https://www.fairvalue-calculator.com/stock/ALSGD
Frequently asked questions
Is Spineguard (ALSGD) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €0.0148 versus a price of €0.0893, about −83% upside (overvalued).
What is the fair value of ALSGD?
Our model-based fair value for Spineguard is €0.0148 (as of Sep 23, 2026), built from audited fundamentals. The current price: €0.0893.
What is the quality score of ALSGD?
Spineguard has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Spineguard (ALSGD)?
Our model-based price target is the fair value of €0.0148 (as of Sep 23, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Spineguard stock forecast for 2026?
Our models put fair value at €0.0148, about −83% upside versus a price of €0.0893 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Spineguard (ALSGD)?
Spineguard reported trailing-twelve-month revenue of about €3.8M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Spineguard (ALSGD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Spineguard it is €0.0148 per share (as of Sep 23, 2026), against a price of €0.0893. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Spineguard stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ALSGD trades above its calculated fair value: price €0.0893, fair value €0.0148, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALSGD?
No. The price is what the market pays today (€0.0893); the fair value is what the company's own numbers justify (€0.0148). For Spineguard the two are €0.0745 per share apart. That gap is exactly why we show both numbers side by side.
How much is Spineguard worth?
The market values Spineguard at about €8.0M (market capitalisation, as of Sep 23, 2026). Per share that is €0.0893; our models calculate a fair value of €0.0148 per share.
How solid is the balance sheet of Spineguard (ALSGD)?
Balance-sheet figures for Spineguard (as of Sep 23, 2026): return on equity −44.1%, debt of 0.14 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is ALSGD from its 52-week high?
Spineguard trades at €0.0893, about 51% below its 52-week high of €0.1824 and 13% above the low of €0.0793 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of €0.0148 is for.
Which stocks are comparable to Spineguard?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Spineguard stock attractive at the current price?
The data as of Sep 23, 2026: price €0.0893, calculated fair value €0.0148 (−83%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALSGD calculated?
We run Spineguard through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.0148, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Spineguard itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Spineguard (ALSGD)?
The closing price on Sep 23, 2026 was €0.0893. Our model-based fair value is €0.0148, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Spineguard right now?
Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Spineguard
How large is the market capitalisation of Spineguard (ALSGD)?
The market capitalisation of Spineguard is €8.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Spineguard (ALSGD)?
The price-to-sales ratio of Spineguard is 2.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Spineguard (ALSGD)?
Earnings per share at Spineguard are €−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Spineguard (ALSGD)?
The net margin of Spineguard is −55.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Spineguard (ALSGD)?
The return on equity (ROE) of Spineguard is −44.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Spineguard (ALSGD)?
On an EBIT basis the return on assets of Spineguard is −23.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Spineguard (ALSGD)?
The operating margin of Spineguard is −56.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Spineguard (ALSGD)?
Revenue at Spineguard is growing −25.7% versus a year earlier (3y avg −12.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Spineguard (ALSGD) generate?
The free cash flow of Spineguard is −€1.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Spineguard (ALSGD) hold?
Spineguard holds more cash than debt, €265K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Spineguard in the live analysis
One click puts Spineguard on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
